Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

COSMBullishCorporate Developmentsnews

High materiality8/10

Cosmos Health Expands European Footprint with Greek DIABIT-IS X Distribution

Jul 13, 2026, 1:04 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Direct revenue visibility from a multi-year contract with a reimbursement-backed market; potential multiple European expansion announcements could re-rate valuation.

AI summary

What happened, with direct paths to the underlying reporting

Cosmos Health signed a five-year Greek commercialization deal for DIABIT-IS X with Libytec, boosting revenue visibility. Cosmos will supply the product via Cana Laboratories, while Libytec handles distribution and promotion under Greece's national health system (EOPYY). The move positions COSM for broader European expansion in a large sitagliptin market, benchmarking against Merck's Januvia/Janumet franchise.

Cosmos Health to supply DIABIT-IS X in Greece; Libytec will distribute and promote.
Five-year agreement to provide revenue and cash-flow visibility for Cosmos.
DIABIT-IS X is a sitagliptin generic; accessible via Greece's EOPYY system.
Januvia/Janumet generated about $4.5B in global sales in 2022; Cosmos gains European exposure.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.